Please contact us for more information or to learn if you are eligible to participate.
The primary objective of this study is to evaluate the efficacy of different doses of NST-4016 on the resolution of NASH without worsening of fibrosis. The secondary objective is to determine the safety and tolerability of NST-4016 in patients with NASH.
Principal Investigator | Sriramachandra Badiga, MD |
Type of Trial | Prospective/Interventional |